Literature DB >> 19795578

Sentinel lymphadenectomy in breast cancer: an update on the NCCN clinical practice guidelines.

Benjamin O Anderson1.   

Abstract

Sentinel lymphadenectomy is an acceptable surgical technique for axillary staging among patients with clinically node-negative stage I or stage II breast cancer with primary invasive tumors measuring less than 5 cm. Patient selection and mapping team experience are critical factors for mapping success and accuracy. In the 2002 NCCN guidelines, exclusion criteria for sentinel node mapping include tumor multicentricity, the use of preoperative (neoadjuvant) chemotherapy or hormonal therapy, and a large excision (more than 6 cm) of the primary tumor performed before mapping. Future studies will clarify whether these exclusions are overly restrictive. Until then, the NCCN guidelines present a conservative perspective on sentinel lymphadenectomy, confirming that complete level I or level II axillary lymph node dissection remains the gold standard for breast cancer axillary staging.

Entities:  

Mesh:

Year:  2003        PMID: 19795578

Source DB:  PubMed          Journal:  J Natl Compr Canc Netw        ISSN: 1540-1405            Impact factor:   11.908


  3 in total

Review 1.  Sentinel node detection in pre-operative axillary staging.

Authors:  Giuseppe Trifirò; Giuseppe Viale; Oreste Gentilini; Laura Lavinia Travaini; Giovanni Paganelli
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-04-22       Impact factor: 9.236

2.  Racial disparities in adoption of axillary sentinel lymph node biopsy and lymphedema risk in women with breast cancer.

Authors:  Dalliah M Black; Jing Jiang; Henry M Kuerer; Thomas A Buchholz; Benjamin D Smith
Journal:  JAMA Surg       Date:  2014-08       Impact factor: 14.766

3.  Imaging of metastatic lymph nodes by X-ray phase-contrast micro-tomography.

Authors:  Torben Haugaard Jensen; Martin Bech; Tina Binderup; Arvid Böttiger; Christian David; Timm Weitkamp; Irene Zanette; Elena Reznikova; Jürgen Mohr; Fritz Rank; Robert Feidenhans'l; Andreas Kjær; Liselotte Højgaard; Franz Pfeiffer
Journal:  PLoS One       Date:  2013-01-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.